AzTrials
AzTrials

Cannabis UseNCT05663346

Cannabis and Cancer, an Online Training for Oncology Nurses

A study testing Cannabis & Cancer digital educational intervention and Standard information regarding cannabis use in oncology in people with Cannabis Use and Cannabis Use, Unspecified, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the preliminary effects and impacts of a digital educational intervention to support nurses' professional practice regarding safe cannabis use by young adults (18-39 years) diagnosed with cancer. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
What is being tested?
Cannabis & Cancer digital educational intervention and Standard information regarding cannabis use in oncology
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
1 siteCanada
Study dates
4 Jan 2024to 18 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Work in an oncology department (eg, radio-oncology, outpatient clinics)
  • Work with people diagnosed with cancer, including young adults
  • Understand, read, and write French

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

Canada1 site

  • Hôpital Maisonneuve-Rosemont

    Montreal, Quebec, H1T 2M4

Other trials in Canada

About this study

Official title: Evaluation of a Digital Educational Intervention Regarding Safe and Efficient Cannabis Use with Young Adults Diagnosed with Cancer: a Pilot Study

The purpose of this study is to evaluate the preliminary effects and impacts of a digital educational intervention to support nurses' professional practice regarding safe cannabis use by young adults (18-39 years) diagnosed with cancer.

Read the detailed description

This online pilot randomized controlled trial with parallel groups is conducted in Quebec (Canada). Moodle learning management system will be used to train nurses working in oncology.

After accepting the conditions and consenting, participants will enroll in the study by providing an email address. Each participant will be validated through an email address check. After their enrolment, participants will receive a hyperlink via email to invite them to complete a baseline questionnaire.

After completing the baseline questionnaire, participants will be randomly assigned by a research assistant to the digital educational intervention (Cannabis \& Cancer) or to a control group (official public websites and scientific articles).

Four weeks after the baseline questionnaire, participants will complete the online questionnaires again.

Being tested
Cannabis & Cancer digital educational intervention, Standard information regarding cannabis use in oncology
Medical subject headings
Cancer Pain, Signs and Symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cannabis & Cancer digital educational interventionOther

    The Cannabis \& Cancer intervention is available on Moodle learning management system in French language. It aims to influence nurses' self-efficacy, attitudes, intentions, and knowledge regarding the safe and efficient use of cannabis by young adults diagnosed with cancer.

  • Standard information regarding cannabis use in oncologyOther

    Participants will be offered basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).

Study groups in NCT05663346
Study groupRoleWhat they receive
Cannabis & Cancer digital educational interventionExperimentalThis intervention includes different asynchronous pedagogical modalities that allow, among other things, to reactivate the participants' previous knowledge and promote their autonomy in their learning process. These modalities focus on various problems that oncology nurses may encounter about the use of cannabis in oncology (eg, how to tackle the subject, what are the correct times to approach the topic). To this end, various pedagogical modalities that encourage the active participation of nurses are integrated into the training (eg, interactive videos, and quizzes). Scientific articles and links to external resources (official public websites) are also included so that nurses can consult the content at their own pace. Different aspects related to the use of cannabis are addressed in the training (eg, beneficial effects, and potential side effects).
Receives: Other: Cannabis & Cancer digital educational intervention
Standard information regarding cannabis use in oncologyActive comparatorThe comparator is composed of an email with basic reliable non-personalized information on cannabis use in oncology (official public websites and scientific articles).
Receives: Other: Standard information regarding cannabis use in oncology

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in self-efficacy

    The French version of the Continuing Professional Development Reaction (CPD-Reaction) questionnaire (Légaré et al., 2014) will be used. The CPD-Reaction is a 12-item theory-based self-report questionnaire designed to assess the impact of continuing professional development on different clinical practices and can be modified according to the behavior targeted by the continuing professional activity (ie, the Cannabis \& Cancer intervention).

    It is scored using a seven-point Likert scale ranging from strongly disagree (1) to strongly agree (7). The total score can range from 3 to 21 for self-efficacy. Higher scores indicate higher levels of self-efficacy. The CPD Reaction has adequate test-retest reliability (ie, weighted kappa coefficient between 0.43-0.53 for self-efficacy). The questionnaire has good internal consistency (Cronbach's alpha = 0.84).

    Measured: 4 weeks

Secondary outcomes (8)

  1. Change in attitudes

    The French version of the Continuing Professional Development Reaction (CPD-Reaction) questionnaire (Légaré et al., 2014) will be used. The CPD-Reaction is a 12-item theory-based self-report questionnaire designed to assess the impact of continuing professional development on different clinical practices and can be modified according to the behavior targeted by the continuing professional activity (ie, the Cannabis \& Cancer intervention).

    It is scored using a seven-point Likert scale ranging from strongly disagree (1) to strongly agree (7). The total score can range from 2 to 14 for attitudes. Higher scores indicate more favorable attitudes toward the behavior. The CPD Reaction has adequate test-retest reliability (ie, weighted kappa coefficient between 0.5-0.54 for attitudes). The questionnaire has good internal consistency (Cronbach's alpha = 0.89).

    Measured: 4 weeks

  2. Change in intention

    The French version of the Continuing Professional Development Reaction (CPD-Reaction) questionnaire (Légaré et al., 2014) will be used. The CPD-Reaction is a 12-item theory-based self-report questionnaire designed to assess the impact of continuing professional development on different clinical practices and can be modified according to the behavior targeted by the continuing professional activity (ie, the Cannabis \& Cancer intervention).

    It is scored using a seven-point Likert scale ranging from strongly disagree (1) to strongly agree (7). The total score can range from 2 to 14 for intention. Higher scores indicate higher intentions to perform the behavior. The CPD Reaction has adequate test-retest reliability (ie, weighted kappa coefficient between 0.54-0.6 for intention). The questionnaire has good internal consistency (Cronbach's alpha = 0.79).

    Measured: 4 weeks

  3. Change in knowledge

    Nurses' knowledge will be assessed using a seven-point Likert scale (ie, 1=strongly disagree and 7=strongly agree) to be developed by the research team based on the educational content presented in the training.

    Measured: 4 weeks

  4. Number of training modules completed by participants (objective engagement)

    Objective data. This data will be collected automatically when users log into the learning management system.

    Measured: 4 weeks

  5. Frequency of viewing modules/participants (objective engagement)

    Objective data. This data will be collected automatically when users log into the learning management system.

    Measured: 4 weeks

  6. Number of logins to the digital educational intervention/participant (objective engagement)

    Objective data. This data will be collected automatically when users log into the learning management system.

    Measured: 4 weeks

  7. Time required to complete all training modules (objective engagement)

    Objective data. This data will be collected automatically when users log into the learning management system.

    Measured: 4 weeks

  8. Subjective engagement with the digital educational intervention

    Subjective engagement (self-reported) will be measured using the validated French version (Fontaine et al., 2020) of the User Engagement Scale - Short Form (UES-SF) (O'Brien et al., 2018). This 12-item instrument serves to measure four dimensions of engagement: 1) aesthetic appeal; 2) focused attention; 3) perceived usability, and 4) reward factor. Possible answers range from strongly disagree (+1) to strongly agree (+5). The possible total score ranges between 12 and 60. The score for each item will be interpreted and the scores for each dimension will be compared to indicate which are rated more highly than others. The French version shows acceptable internal consistency (ie, McDonald's omega coefficients ranging from 0.77-0.89).

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2022
  2. Study start4 Jan 2024
  3. Primary completion18 Mar 2024
  4. Study completion18 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
70 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05663346
Sponsor's protocol ID
2022-2802
Status last verified
Feb 2025
First submitted
15 Dec 2022
Last updated
14 Feb 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Vinette B, Cote J, Bilodeau K. Evaluation of a Digital Educational Intervention to Enhance Oncology Nurse Professional Practice to Support Safe Cannabis Use: A Pilot Study. J Contin Educ Health Prof. 2026 Spring 01;46(2):81-87. doi: 10.1097/CEH.0000000000000631. Epub 2025 Dec 17.

    PubMed 41427816

Questions about this trial

What is this clinical trial studying?

A study testing Cannabis & Cancer digital educational intervention and Standard information regarding cannabis use in oncology in people with Cannabis Use and Cannabis Use, Unspecified, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in self-efficacy (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05663346, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in